title: Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors.
abstract: The transcription factor p53 and its negative regulator MDM2 are pivotal in normal and cancer cells biology. Recently, a functional single-nucleotide polymorphism in the promoter region of MDM2 (MDM2 SNP309), alone or in combination with TP53 R72P, was shown to be associated with the risk, prognosis, age at onset, molecular markers, and response to chemotherapy of various cancers. This SNP has never been specifically investigated in a large series of oligodendroglial tumors. In a comparison with 232 healthy controls, we retrospectively analyzed blood samples of 293 oligodendroglial tumor patients for MDM2 SNP309. In addition, the TP53 R72P polymorphism and chromosome 1p/19q status, a major biomarker in oligodendroglial tumors, were investigated. The frequencies of T/T, T/G, and G/G genotypes in patients and controls did not suggest an increased risk of oligodendroglial tumor formation correlating with MDM2 SNP309. A borderline association was found between MDM2 SNP309 and overall survival (p=0.05), but in multivariate analysis, MDM2 SNP309 did not provide prognostic information complementary to age, tumor phenotype, grade, and 1p/19q status in oligodendroglial tumors. Finally, MDM2 SNP309, alone or in combination with TP53 R72P, was not associated with oligodendroglial tumors.
authors.affiliation: INSERM, Unité 711, Paris, Université Pierre et Marie Curie-Paris6, Laboratoire Biologie des Interactions Neurone-Glie, Groupe hospitalier Pitié-Salpêtrière, Paris, France. ahmed.idbaih@gmail.com
authors.forename: Ahmed
authors.initials: A
authors.lastname: Idbaih
authors.forename: Blandine
authors.initials: B
authors.lastname: Boisselier
authors.forename: Yannick
authors.initials: Y
authors.lastname: Marie
authors.forename: Marc
authors.initials: M
authors.lastname: Sanson
authors.forename: Soufiane
authors.initials: S
authors.lastname: El Hallani
authors.forename: Emmanuelle
authors.initials: E
authors.lastname: Crinière
authors.forename: Maryam
authors.initials: M
authors.lastname: Fourtassi
authors.forename: Sophie
authors.initials: S
authors.lastname: Paris
authors.forename: Catherine
authors.initials: C
authors.lastname: Carpentier
authors.forename: Audrey
authors.initials: A
authors.lastname: Rousseau
authors.forename: Karima
authors.initials: K
authors.lastname: Mokhtari
authors.forename: Christophe
authors.initials: C
authors.lastname: Combadière
authors.forename: Florence
authors.initials: F
authors.lastname: Laigle-Donadey
authors.forename: Khê
authors.initials: K
authors.lastname: Hoang-Xuan
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Delattre
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D001932:Brain Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000503:physiopathology; D002878:Chromosomes, Human, Pair 1 / Q000235:genetics; D004252:DNA Mutational Analysis; D005260:Female; D020022:Genetic Predisposition to Disease / Q000235:genetics*; D005820:Genetic Testing; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D009837:Oligodendroglioma / Q000235:genetics* / Q000378:metabolism / Q000503:physiopathology; D010641:Phenotype; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*; D011379:Prognosis; D051736:Proto-Oncogene Proteins c-mdm2 / Q000235:genetics*; D012189:Retrospective Studies; D015996:Survival Rate; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*
chemical_list: C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2